Antibody Engineering & Therapeutics Europe 2025 was held in Basel, Switzerland, on 10-12 June 2025. As Europe's leading antibody conference for accelerating next-generation antibodies to commercial success, topics discussed included:
Innovations in Antibody Discovery: Emerging in vitro and advanced in vivo discovery approaches
Next-Generation Antibody Engineering: Fc engineering, multi-specifics, and novel therapeutic scaffolds
Expanding Therapeutic Applications: Autoimmune diseases, non-oncology indications, and combination therapies
Targeted and Functional Enhancements: Agonist antibodies, co-stimulatory mechanisms, and antibody-payload innovations
→ Biointron’s Highlighted Points:
1. Therapeutic Antibody Applications Beyond Oncology
Trim-Away technology harnesses the cytosolic Fc receptor TRIM21 to degrade intracellular proteins via antibody targeting, and recent work highlights its application in removing tau aggregates in vivo in an Alzheimer’s mouse model. (MRC Laboratory of Molecular Biology)
TV-enabled antibodies targeting microglial function are being developed to enhance brain exposure, biodistribution, and target engagement in Alzheimer’s disease, leveraging human genetics to guide therapeutic discovery. (Denali Therapeutics)
Metabolic modifiers can reshape the tumor immune environment and, when combined with checkpoint blockade, enhance therapeutic responses, highlighting the importance of host metabolic factors in immunotherapy development. (University of Southampton)
2. Beyond IgG: Next-gen Therapeutic Scaffolds & Antibody Formats
TandemAb combines structural features of IgA and IgG to create antibody formats with improved half-life and enhanced effector engagement for targeted killing of cancer cells and bacteria. (University of Oslo)
IgE antibodies engineered to target cancer-associated antigens can reprogram the tumor microenvironment by recruiting pro-inflammatory effectors and inducing hyperinflammatory macrophages, offering a novel immunotherapeutic strategy. (King’s College London)
Engineered IgM antibodies, with high avidity and potent effector functions, show strong therapeutic potential across cancer, infectious, and autoimmune diseases, as production and characterization challenges are being overcome. (MultiValent Biotherapeutics)
3. Antibodies For Autoimmune Disease
A first-in-class soloMER drug conjugate has been developed to site-deliver a potent anti-inflammatory JAK inhibitor via multivalent anti-TNFα binding, addressing unmet needs in autoimmune and inflammatory diseases. (Elasmogen)
CLN-978, a novel CD19/CD3-bispecific T cell engager, is in clinical trials for rheumatoid arthritis and systemic lupus erythematosus, leveraging potent B cell depletion to drive remission in autoimmune diseases. (Cullinan Therapeutics)
ARGX-117, a recycling anti-C2 antibody, was developed to inhibit complement activation and is now in phase 2 studies, demonstrating therapeutic potential for multifocal motor neuropathy. (UMC Utrecht)
4. Enhanced Therapeutic Function Though Fc Engineering
Stellabody, a CH3 region point mutation, enables on-target assembly of immune biologics and enhances killing or agonistic potency 10–100x across formats including mAbs, bispecifics, and Fc-fusions. (Burnet Institute)
Complex antibody formats impact pharmacokinetic properties through FcRn-mediated recycling, as revealed by structure-PK relationship studies in vitro and in SDPK mouse models. (Roche)
5. Multi-Specific Engineering
Novel anti-CD3 heavy chain-only antibodies enable flexible, manufacturable T cell-engaging multispecific therapeutics with potent cytotoxicity, offering a streamlined alternative to conventional TCE formats. (Adimab)
BON-001 is a conditionally active IL-2 therapeutic that targets LAG3+ cells via dual-binding antibody technology, enhancing tumor-specific CD8+ T cell responses and synergizing with anti-PD-1 in preclinical cancer models. (Bonum Therapeutics)
Antibody-cytokine fusions engineered with cytokine muteins and functional masking units enable localized, conditionally activated cytokine activity in the tumor microenvironment, enhancing tumor cell killing while attenuating systemic potency. (Technical University of Darmstadt)
Thank you to everyone who visited our booth at AET Europe 2025 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com
